Global pharmaceutical company Bristol-Myers Squibb (NASDAQ: BMY) announced the FDA approval of Sprycel™ (dasatinib) on June 28, 2006. The new medication was approved for two indications: treatment of adults in all phases of chronic myeloid leukemia (CML) (chronic, accelerated, or myeloid or lymphoid blast phase) with resistance or intolerance to prior therapy, including Gleevec® (imatinib mesylate), and treatment of adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) with resistance or intolerance to prior therapy.
